Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. In June 2021, Novo Nordisk won ...

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon confirm that.